We found that simultaneous inhibition of EGFR and VEGFR2 signaling pathways with delphinidin may offer greater anti-tumor efficacy for advanced NSCLC than inhibitors of either pathway alone. This evidence concerns the gene EGFR and non-small cell lung carcinoma.